The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group DREAMS-3 is the world's ...
CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ --MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive ...
Is sugar or calories more important for blood sugar? Learn how each affects glucose, why both matter, and practical tips to build balanced meals for better blood sugar control.
As the world's first approved GCG/ GLP-1 dual receptor agonist, mazdutide has demonstrated superior efficacy in glucose lowering and weight loss over semaglutide in the latest Phase 3 clinical trial; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results